| Medication Category | GLP-1 receptor agonists, a class of medications that mimic the effects of glucagon-like peptide-1. | Sodium-glucose cotransporter-2 inhibitors, a class of medications that reduce glucose reabsorption in the kidneys. |
| Common Medications and Brands | - Semaglutide: Ozempic, Wegovy, and certain oral semaglutide products.
- Liraglutide: Victoza and Saxenda.
- Dulaglutide: Trulicity.
- Related Medication: Tirzepatide (Mounjaro and Zepbound) activates both GIP and GLP-1 receptors.
| - Empagliflozin: Jardiance.
- Dapagliflozin: Farxiga.
- Canagliflozin: Invokana.
- Ertugliflozin: Steglatro.
|
| Manufacturer | Multiple pharmaceutical manufacturers, including Novo Nordisk and Eli Lilly, depending on the medication. | Multiple pharmaceutical manufacturers, including Boehringer Ingelheim, Eli Lilly, AstraZeneca, Janssen, and Merck, depending on the medication and market. |
| Pricing | - Brand-Name Costs: Many GLP-1 medications have high retail prices, potentially reaching several hundred dollars or more per month without insurance.
- Manufacturer Programs: Savings programs and self-pay offers may reduce costs for eligible patients.
- Out-of-Pocket Expenses: Depend on the specific medication, dosage, pharmacy, insurance coverage, and available discounts.
| - Brand-Name Costs: Many SGLT2 inhibitors also have high retail prices, potentially costing several hundred dollars per month without insurance.
- Generic Availability: Varies by medication and market, potentially affecting affordability.
- Out-of-Pocket Expenses: Depend on the prescribed drug, pharmacy, insurance coverage, and manufacturer savings eligibility.
|
| Insurance Coverage | - Type 2 Diabetes: Many plans cover certain GLP-1 medications for eligible patients.
- Weight Management: Coverage varies considerably by medication, indication, and insurance plan.
- Prior Authorization: May require documentation of diagnosis, medical necessity, or previous treatments.
| - Type 2 Diabetes: Many insurance plans cover certain SGLT2 inhibitors for eligible patients.
- Heart Failure and Kidney Disease: Coverage may be available for approved indications even without a diabetes diagnosis.
- Prior Authorization: Some plans require medical documentation or preferred-drug criteria.
|
| Main Purpose | Improve blood sugar control in type 2 diabetes or support chronic weight management, depending on the specific medication and its approved indications. | Improve blood sugar control in type 2 diabetes and, for certain medications, reduce risks associated with heart failure or chronic kidney disease. |
| Secondary Purposes | - Cardiovascular Protection: Certain medications reduce major cardiovascular events in specified patient populations.
- Kidney Protection: Certain GLP-1 medications have demonstrated kidney-related benefits in eligible patients.
- Weight Management: Specific GLP-1 medications are approved for long-term weight reduction and maintenance.
| - Heart Failure: Certain SGLT2 inhibitors reduce heart failure hospitalization and other specified risks.
- Kidney Protection: Certain medications slow chronic kidney disease progression in eligible patients.
- Blood Pressure and Weight: May produce modest reductions in blood pressure and body weight.
|
| How It Works | - Insulin Secretion: Stimulates glucose-dependent insulin release.
- Glucagon Regulation: Reduces inappropriate glucagon secretion.
- Appetite Regulation: Acts on pathways involved in hunger and fullness.
- Gastric Emptying: Slows stomach emptying to varying degrees.
| - Kidney Glucose Reabsorption: Blocks SGLT2 proteins in the kidneys.
- Urinary Glucose Excretion: Increases the amount of glucose eliminated through urine.
- Fluid and Sodium Handling: Alters kidney handling of sodium and fluid, contributing to certain cardiovascular and kidney effects.
|
| Blood Sugar Control | GLP-1 medications can produce substantial HbA1c reductions in patients with type 2 diabetes. Effectiveness varies by medication, dosage, baseline HbA1c, and treatment duration. | SGLT2 inhibitors commonly reduce HbA1c by approximately 0.5–1 percentage point in patients with type 2 diabetes, although the response varies with baseline glucose levels, kidney function, and the specific medication. |
| Weight Loss Potential | GLP-1 medications generally produce greater weight loss than SGLT2 inhibitors. Certain obesity-approved GLP-1 medications have produced average body-weight reductions exceeding 10% in major clinical trials, depending on the medication, dose, and study population. | SGLT2 inhibitors generally produce modest weight loss, often approximately 2–3 kg in patients with type 2 diabetes. They are not FDA-approved specifically for weight management. |
| Appetite Suppression | Many GLP-1 medications directly affect appetite-regulating pathways, reducing hunger, increasing fullness, and decreasing food intake. | SGLT2 inhibitors do not directly suppress appetite. Weight loss occurs primarily through urinary glucose and calorie loss, and compensatory increases in appetite may limit the effect. |
| Cardiovascular Benefits | Certain GLP-1 medications reduce major cardiovascular events, including heart attack or stroke, in specified patient populations. Benefits vary by medication and approved indication. | Certain SGLT2 inhibitors reduce heart failure hospitalization and other cardiovascular risks. Some also reduce major cardiovascular events in eligible patients with type 2 diabetes and established cardiovascular disease. |
| Heart Failure Benefits | GLP-1 receptor agonists are not generally the preferred medication class specifically for reducing heart failure hospitalization, although individual medications may offer benefits in selected heart failure populations. | SGLT2 inhibitors have strong evidence for reducing heart failure hospitalization and improving certain clinical outcomes in eligible patients with heart failure, including some without diabetes. |
| Kidney Health | Certain GLP-1 medications reduce kidney-related risks in specified patients with type 2 diabetes and chronic kidney disease. Benefits and approved indications vary by drug. | Certain SGLT2 inhibitors slow chronic kidney disease progression and reduce kidney-related complications in eligible patients, including some without diabetes. |
| Blood Pressure Effects | GLP-1 medications may produce modest blood pressure reductions, particularly alongside weight loss. | SGLT2 inhibitors may modestly lower blood pressure through their effects on urinary glucose, sodium, and fluid excretion. |
| Administration | - Weekly Injections: Several GLP-1 medications are administered by subcutaneous injection once weekly.
- Daily Injections: Certain GLP-1 medications require daily injections.
- Oral Options: Oral semaglutide formulations are available with specific administration requirements.
| - Oral Tablets: SGLT2 inhibitors are generally taken by mouth once daily.
- Administration Schedule: Timing and food requirements depend on the prescribed medication.
- Injections: Not required for standard SGLT2 inhibitor treatment.
|
| Dosing Considerations | - Starting Dose: Depends on the specific GLP-1 medication.
- Dose Escalation: Many treatments require gradual increases to improve gastrointestinal tolerability.
- Maintenance Dose: Selected according to treatment indication, response, and tolerability.
| - Starting Dose: Depends on the prescribed SGLT2 inhibitor and treatment indication.
- Kidney Function: Eligibility, initiation thresholds, and glucose-lowering effectiveness depend partly on eGFR.
- Dose Adjustment: Some medications allow dose increases for additional glucose control, while others use a fixed dose for specific indications.
|
| Potential Side Effects | - Digestive Symptoms: Nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
- Appetite Changes: Reduced hunger and early fullness.
- Injection-Site Reactions: Possible with injectable formulations.
- Timing: Gastrointestinal symptoms frequently occur when beginning treatment or increasing dosage.
| - Genital Yeast Infections: Increased risk due to glucose in urine.
- Increased Urination: More frequent urination may occur.
- Thirst and Dizziness: Possible from fluid loss and reduced blood pressure.
- Urinary Tract Infections: May occur, including rare serious infections.
|
| Potential Health Risks | - Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Thyroid Warning: Several GLP-1 medications carry a boxed warning concerning thyroid C-cell tumors observed in rodents.
| - Diabetic Ketoacidosis: Potentially serious ketoacidosis that can occur even without markedly elevated blood glucose.
- Volume Depletion: Dehydration and low blood pressure, particularly in susceptible patients.
- Serious Infections: Rare severe urinary infections or necrotizing infections of the perineum.
- Medication-Specific Risks: Certain additional warnings, including amputation-related concerns, vary by drug.
|
| Hypoglycemia Risk | Generally low when used alone, but the risk increases when combined with insulin or sulfonylureas. | Generally low when used alone, but the risk increases when combined with insulin or sulfonylureas. |
| Who May Benefit Most? | Eligible patients with type 2 diabetes who need improved blood sugar control and weight reduction, particularly those who may benefit from a specific medication’s cardiovascular or kidney protection. Certain GLP-1 medications also benefit eligible patients with obesity without diabetes. | Eligible patients with type 2 diabetes, heart failure, or chronic kidney disease who may benefit from the medication’s glucose-lowering, cardiovascular, or kidney-protective effects. Some SGLT2 inhibitors are appropriate for qualifying patients without diabetes. |
| How Fast Does It Work? | - Blood Sugar: Improvements may begin within the first weeks.
- HbA1c: Treatment effectiveness is commonly evaluated after approximately three months.
- Weight Loss: Develops gradually over several months, with results depending on medication, dose, and treatment duration.
| - Urinary Glucose Excretion: Begins soon after treatment starts.
- Blood Sugar: Improvements may begin within days, with HbA1c commonly reassessed after approximately three months.
- Weight Loss: Modest reductions generally develop over several weeks to months.
|
| Can They Be Taken Together? | Yes. A GLP-1 receptor agonist may be prescribed alongside an SGLT2 inhibitor when the combination is clinically appropriate for blood sugar control or other treatment goals. | Yes. An SGLT2 inhibitor may be combined with a GLP-1 receptor agonist to address complementary metabolic, cardiovascular, or kidney-related treatment needs. |